Inclusion Criteria:

• Male or female 18 years of age or older.
• Diagnosis of at least two episodes of recurrent pericarditis*.
• At least 1 day with pericarditis pain ≥4 on the 11-point Numerical Rating Scale (NRS) within prior 7 days.
• One of:
  • C-Reactive Protein** (CRP) level ≥ 1.0 mg/dL within prior 7 days; OR
  • Evidence of pericardial inflammation assessed by delayed pericardial hyperenhancement on cardiac magnetic resonance imaging (CMR).
• Has received non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination) in stable doses for at least 3 days prior to enrolment.
• Male patients with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug.
• Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] ≥ 40 mIU/mL [or ≥ 40 IU/L] if less than 2 y postmenopausal) or be surgically sterile.
• Diagnosis of pericarditis according to the 2015 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Pericardial Diseases (Adler et al. 2015):
• At least two of:
  • Pericarditic chest pain;
  • Pericardial rub;
  • New widespread ST-segment elevation or PR-segment depression according to electrocardiogram (ECG) findings;
  • Pericardial effusion (new or worsening);
  • Conversion: 1 mg/dL CRP = 10 mg/L hs-CRP.

Exclusion Criteria:

• Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); myocarditis.
• Estimated glomerular filtration rate (eGFR) < 30 mL/min.
• Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or ALT or AST > 3 x ULN plus bilirubin > 2 x ULN.
• Sepsis, defined as documented bacteremia at the time of presentation or other documented active infection.
• History of QT interval prolongation.
• QTc interval > 500 msec.
• Current participation in any research study involving investigational drugs or device.
• Inability or unwillingness to give informed consent.
• Ongoing drug or alcohol abuse.
• On any cannabinoid during the past month.
• Women who are pregnant or breastfeeding.
• Current diagnosis of cancer, with the exception of non-melanoma skin cancer.
• Any factor, which would make it unlikely that the patient can comply with the study procedures.
• Body weight > 170 kg.
• Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS), administered at screening.
• On immunosuppressive therapy with any of the following:
  • Rilonacept;
  • Anakinra;
  • Canakinumab.
• Methotrexate.
• Azathioprine.
• Cyclosporine.
• Intravenous immune globulin (IVIG).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/29/22. Questions regarding updates should be directed to the study team contact.